Semaglutide vs Tirzepatide: Which Is Right for You?

The Two Leading GLP-1 Medications

Semaglutide (Ozempic/Wegovy) and tirzepatide (Mounjaro/Zepbound) are the two dominant medications in the GLP-1 weight loss category. Both are weekly injections that suppress appetite and improve metabolic health, but they work through different mechanisms and show different levels of efficacy.

How They Work

Semaglutide is a GLP-1 receptor agonist — it mimics the GLP-1 hormone to reduce appetite, slow gastric emptying, and improve insulin sensitivity. Tirzepatide is a dual GIP/GLP-1 receptor agonist — it activates both the GLP-1 and GIP pathways, which appears to provide greater metabolic benefit.

• ✓Semaglutide: Single target (GLP-1 only)
• ✓Tirzepatide: Dual target (GLP-1 + GIP) — first-in-class dual agonist
• ✓Both reduce appetite, slow digestion, and improve blood sugar control
• ✓Tirzepatide may have additional effects on fat metabolism through the GIP pathway

Weight Loss Results

Clinical trials show tirzepatide produces greater average weight loss than semaglutide. In the SURMOUNT trials, tirzepatide at the highest dose produced average weight loss of 22.5% of body weight. In the STEP trials, semaglutide at 2.4mg produced average weight loss of 14.9%. However, individual results vary significantly.

Side Effects Comparison

Both medications share similar GI side effects, though the severity and profile differ slightly.

• ✓Nausea: Similar rates (both ~30-40% initially, decreasing over time)
• ✓Constipation: More common with semaglutide
• ✓Diarrhea: Slightly more common with tirzepatide
• ✓Both: slow titration dramatically reduces side effect severity
• ✓Rare but serious: pancreatitis risk with both, thyroid C-cell tumors in animal studies

Cost & Availability

Brand-name versions of both medications are expensive ($800-1,300/month without insurance). Compounding pharmacies offer semaglutide and tirzepatide at significantly lower cost ($200-500/month). Insurance coverage varies widely. Semaglutide has been available longer and has broader insurance coverage for diabetes, while weight-loss-specific formulations often require prior authorization.

How to Choose

The right choice depends on your goals, medical history, and response. If maximal weight loss is the priority and cost is not a barrier, tirzepatide generally produces better results. If you have type 2 diabetes, both are excellent but tirzepatide shows stronger glucose control. If you have tried semaglutide without adequate results, switching to tirzepatide often produces further weight loss. Always work with a qualified provider who can monitor labs and adjust your protocol.